- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI files for approval of FS069
Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In
Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In addition,MBI hopes to get approval to use the agent for opacification ofthe left ventricular chamber. MBI has granted Mallinckrodt Medicallicenses to market FS069 in the U.S. and in a number of internationalmarkets (SCAN 12/18/96).
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
